Market Trends of Global Endometrial Cancer Industry
This section covers the major market trends shaping the Endometrial Cancer Market according to our research experts:
The Chemotherapy Segment Expected to Witness a Growth in the Endometrial Cancer Market Over the Forecast Period
The chemotherapy segment is expected to witness growth in the endometrial cancer market owing to the factors such as the increasing prevalence of endometrial cancer requiring chemotherapies and the rise in chemotherapy product developments. Chemotherapy is widely accepted for endometrial cancer since, after surgery, chemotherapy (chemo) with or without radiation therapy is given to help keep cancer from coming back. For instance, as per an article published in February 2022 in PubMed, combining the two drugs (Lenvatinib plus Pembrolizumab) led to longer progression-free survival and overall survival among patients than chemotherapy. Furthermore, per the statistics by the American Cancer Society updated in 2022, there were more than 600,000 endometrial cancer survivors in the United States. As per the same source, around 65,950 new cases of cancer of the body of the uterus (uterine body or corpus) were expected to be diagnosed in 2022. Thus, the demand for chemotherapy may rise with the growing burden of endometrial cancer.
According to the American Cancer Society, endometrial cancer is treated with chemotherapy drugs such doxorubicin (Adriamycin) or liposomal doxorubicin (Doxil), cisplatin, and docetaxel (Taxotere). Furthermore, as per a study published in January 2022 in PubMed, front-line treatment for women with advanced endometrial cancer was firmly established as platinum-based chemotherapy plus taxane. Such studies indicate the efficacy of chemotherapy in the treatment of endometrial cancer. Furthermore, as per an article published in June 2022 by PubMed, over 90% of patients who got adjuvant chemotherapy for endometrial cancer and underwent hysterectomy also received platinum-taxane combination chemotherapy, and nearly 70% of patients who recurred initially were given platinum- or taxane-based therapy. Similarly as per an article published in October 2022 in MDPI, researchers found that the addition of trastuzumab to chemotherapy for high expressers of Her2/neu in endometrial serous carcinoma improved overall survival. Owing to such advantages offered by chemotherapy in endometrial cancer survival, the segment is likely to witness growth over the forecast period.
North America is Anticipated to Witness a Growth in the Endometrial Cancer Market Over the Forecast Period
North America is expected to witness growth in the endometrial cancer market over the forecast period owing to factors such as the rising awareness of the diagnosis of cancer and the country's well-developed healthcare infrastructure. The American Cancer Society estimated about 65,950 new cases of cancer of the body of the uterus (uterine body or corpus) were likely to be diagnosed in the United States. Endometrial cancer affects mainly post-menopausal women. The average age of women diagnosed with endometrial cancer is 60.
Furthermore, there are many clinical studies of endometrial cancer conducted in the studied region. For instance, in July 2022, Canada-based Sunnybrook Health Sciences Centre sponsored a clinical study to assess the effect of megestrol acetate on grade 2 endometrioid endometrial cancer in patients waiting for definitive surgery. Moreover, several market players are engaged in the implementation of strategic initiatives across the region. For instance, in February 2022, Karyopharm Therapeutics Inc., based in the United States, reported positive top-line results from the Phase 3 Selinexor endometrial cancer study, evaluating the efficacy and safety of front-line maintenance therapy using selinexor in patients with advanced or recurrent endometrial cancer.
